What is he best known for?
The fields of study he is best known for:
Bernard Mach spends much of his time researching Genetics, Gene, Bare lymphocyte syndrome, Regulation of gene expression and MHC Class II Gene.
His MHC class II, Major histocompatibility complex, Human leukocyte antigen, MHC class I and Promoter study are his primary interests in Genetics.
The various areas that Bernard Mach examines in his Bare lymphocyte syndrome study include Regulator gene and RFXANK.
His work carried out in the field of MHC Class II Gene brings together such families of science as CIITA and CIITA Gene.
Bernard Mach has included themes like RFX5 and Cell biology in his CIITA Gene study.
The CD74 study combines topics in areas such as Molecular biology and Transporter associated with antigen processing.
His most cited work include:
- Nomenclature for factors of the HLA system, 2010. (1906 citations)
- Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome) (734 citations)
- Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA (681 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Genetics, Molecular biology, Gene, Human leukocyte antigen and Major histocompatibility complex.
His study in Genetics focuses on Allele, Locus, MHC class II, Haplotype and Bare lymphocyte syndrome.
His research in MHC class II intersects with topics in Complementation and MHC class I.
His Molecular biology research integrates issues from Plasmid, DNA, Complementary DNA, Messenger RNA and HLA-DR Antigen.
His work on Histocompatibility and Nomenclature Committee as part of general Human leukocyte antigen research is frequently linked to Library science, thereby connecting diverse disciplines of science.
His Major histocompatibility complex research incorporates elements of Receptor, Gene expression and Antigen presentation.
He most often published in these fields:
- Genetics (52.25%)
- Molecular biology (37.84%)
- Gene (34.23%)
What were the highlights of his more recent work (between 1995-2013)?
- Genetics (52.25%)
- CIITA (10.36%)
- MHC class II (18.02%)
In recent papers he was focusing on the following fields of study:
Bernard Mach focuses on Genetics, CIITA, MHC class II, MHC Class II Gene and Cell biology.
His works in Gene, Bare lymphocyte syndrome, Complementation, Regulation of gene expression and Promoter are all subjects of inquiry into Genetics.
Gene connects with themes related to Human leukocyte antigen in his study.
His CIITA research is multidisciplinary, incorporating perspectives in RFX5, CIITA Gene and Transactivation.
His MHC class II study combines topics in areas such as Cancer, MHC class I, Pharmacology and Tissue transplantation.
The MHC Class II Gene study which covers Gene expression that intersects with Transcription and Molecular biology.
Between 1995 and 2013, his most popular works were:
- Nomenclature for factors of the HLA system, 2010. (1906 citations)
- REGULATION OF MHC CLASS II GENES: Lessons from a Disease (464 citations)
- The bare lymphocyte syndrome and the regulation of MHC expression. (460 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Genetics, CIITA, Regulation of gene expression, MHC Class II Gene and CIITA Gene.
In general Genetics, his work in Bare lymphocyte syndrome, RFXANK, Gene and DNA-binding protein is often linked to Databases as Topic linking many areas of study.
His study in the fields of Retrovirus under the domain of Gene overlaps with other disciplines such as Mammary tumor.
CIITA is closely attributed to RFX5 in his study.
The study incorporates disciplines such as IRF1 and E-box in addition to Regulation of gene expression.
His study in MHC Class II Gene is interdisciplinary in nature, drawing from both Transactivation and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
